Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2024-04-01 Board/Management Inform…
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Change in Director(s)
Board/Management Information Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the appointment of new Independent Directors on the Board of Directors of the company. It details the appointments, committee reconstitutions, and includes an annexure with profiles and compliance information. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes no financial statements or financial performance data. It is a formal announcement of changes in the company's board composition and committee structure, which fits the category of Board/Management Information (MANG). The document length is over 10,000 characters and contains detailed information about management changes, not just a brief notice or a report publication announcement. Therefore, the correct classification is MANG with high confidence.
2024-04-01 English
Appointment
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the appointment of new Independent Directors and the reconstitution of various board committees. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the appointments, committee compositions, and related disclosures. There are no financial statements, earnings data, or audit information present. The content focuses on changes in the company's board and management structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length (10,264 characters) is sufficient to contain detailed information, not just a brief announcement, supporting the classification as a management information filing rather than a simple notice or regulatory filing.
2024-04-01 English
Appointment
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the appointment of new Independent Directors and the reconstitution of various board committees. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the appointments and committee compositions. The document includes no financial statements or financial performance data but focuses on changes in the company's board and management structure. It also mentions the approval of a postal ballot notice for shareholder approval of these appointments. Given these characteristics, the document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-04-01 English
Outcome of Board Meeting
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the appointment of new Independent Directors and the reconstitution of various board committees. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the appointments, committee compositions, and related disclosures. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and management structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length (10,264 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2024-04-01 English
Change in Director(s)
Regulatory Filings
2024-03-30 English
Cessation
Regulatory Filings
2024-03-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.